Proposal for an anti-TNF-exit strategy based on trough serum level

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Anti-tumor necrosis factor (anti-TNF) therapies are crucial for inflammatory bowel disease (IBD) management.
• Discontinuation strategies for anti-TNF treatment require optimization to minimize relapse rates.
• Monitoring trough serum levels and excluding active inflammation are key factors in treatment decisions.

Purpose of the Study:

• To evaluate if an anti-TNF treatment cessation strategy based on low trough serum levels and absence of inflammation reduces relapse rates in IBD patients.
• To compare relapse rates between patients discontinuing anti-TNF therapy using a defined algorithm versus a control group.

Main Methods:

• A prospective observational study with retrospective data analysis was conducted.
• An exit strategy involving monitoring anti-TNF trough serum levels and excluding inflammation was implemented since 2013.
• Forty IBD patients who stopped anti-TNF therapy were analyzed, with 13 following the algorithm and 27 serving as controls.

Main Results:

• Relapses were observed in 55% of patients (22/40) overall.
• Patients discontinuing anti-TNF therapy based on the algorithm experienced significantly lower relapse rates (23%) compared to the non-algorithm group (70%).
• Relapse-free survival was significantly higher in the algorithm-guided group (p=0.032), with an odds ratio of 7.9 for relapse in the non-algorithm group.

Conclusions:

• An exit strategy for anti-TNF therapy guided by trough serum levels and inflammation assessment significantly reduces post-discontinuation relapse rates in IBD.
• This targeted approach improves clinical outcomes and relapse-free survival.
• Monitoring drug levels and inflammatory status is a viable strategy for optimizing anti-TNF treatment cessation in IBD.